David Rogers, PharmD, PhD, professor of Clinical Pharmacy and vice chair of Research, has been formally invited to become a member of the Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section at the National Institutes of Health (NIH). He will serve for a six-year term. Dr. Rogers was selected on the basis of his demonstrated competence and achievement in his scientific discipline evidenced by his research accomplishments, publications, and other significant scientific activities, achievements, and honors.
The Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) Study Section is responsible for reviewing applications regarding the identification of novel antimicrobial, antifungal, and antiparasitic agents for the treatment and prevention of infectious diseases. The section is charged with the study of evolution, mechanisms and transmission of resistance. Study sections review grant applications submitted to the NIH, make recommendations on these applications to the appropriate national advisory council or board, and survey the status of research in their fields of science.
Dr. Rogers is currently celebrating his tenth year of consecutive NIH funding for his work on azole antifungal drug resistance. This has been a long-running R01-funded project for which Dr. Rogers is the PI. He is a University of Tennessee College of Pharmacy alumnus. He also obtained a Master’s degree and PhD in Microbiology from the University of Mississippi. His primary focus area is the management of infections due to Candida albicans.